Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Update

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 81,000 shares, a drop of 48.1% from the March 31st total of 156,200 shares. Based on an average trading volume of 69,200 shares, the short-interest ratio is presently 1.2 days. Currently, 0.5% of the company’s stock are sold short.

Sensei Biotherapeutics Stock Up 2.0 %

Shares of NASDAQ SNSE traded up $0.02 during midday trading on Friday, hitting $1.02. 6,161 shares of the stock traded hands, compared to its average volume of 92,672. Sensei Biotherapeutics has a one year low of $0.51 and a one year high of $1.72. The business has a 50 day moving average price of $0.97 and a two-hundred day moving average price of $0.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.92 and a current ratio of 11.92. The company has a market cap of $25.57 million, a PE ratio of -0.84 and a beta of 0.17.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. On average, equities analysts predict that Sensei Biotherapeutics will post -0.97 EPS for the current year.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.